Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.
Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca's ESOT-01.
Pharmaceutical Technology
Early data suggest KLN-1010, now acquired by Eli Lilly, could be more tolerable but less efficacious that AstraZeneca’s ESOT-01.